Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BTZ2

UPID:
DHRS4_HUMAN

ALTERNATIVE NAMES:
NADPH-dependent carbonyl reductase; NADPH-dependent retinol dehydrogenase/reductase; Peroxisomal short-chain alcohol dehydrogenase; SCAD-SRL; Short chain dehydrogenase/reductase family 25C member 2; Short-chain dehydrogenase/reductase family member 4

ALTERNATIVE UPACC:
Q9BTZ2; B2RB10; B7WNS9; D3YTB8; E2QRL8; O95162; Q20CR0; Q2LC19; Q2LE81; Q58IU4; Q6E0Y1; Q6UWU3; Q71UQ6; Q8TD03; Q9H3N5; Q9NV08

BACKGROUND:
The Dehydrogenase/reductase SDR family member 4, known alternatively as NADPH-dependent carbonyl reductase, participates in the reduction of carbonyl groups across a spectrum of compounds. Its activity towards xenobiotic alpha-dicarbonyl compounds, such as benzil, highlights its involvement in detoxification processes. The enzyme's distinct selectivity for 3beta-hydroxysteroids over 3alpha-hydroxysteroids sets it apart from its non-primate counterparts.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Dehydrogenase/reductase SDR family member 4 unveils promising avenues for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.